Recent Posts

Apr
08

Mesothelioma Prognosis

What factors facilitate confirm a mesothelioma prognosis?

When a personal is diagnosed with mesothelioma or the other quite cancer, one among the primary queries can they’ll have is “How long do I actually have to live?” this is often a scary question – and a tough one to raise – however one that most cancer patients will eventually ask for a solution.

It is typically terribly tough for oncologists and members of a patient’s medical team to convey a definitive answer to the current question. Indeed, each case is completely different and cancer are often hit and miss disease. Sometimes, cases that look hopeless prove to be not therefore bleak. In alternative cases, cancers that don’t look therefore dangerous progress quickly and lead to an untimely death.

Overall, the prognosis has been rather grim for mesothelioma patients throughout these past few decades. Malignant mesothelioma is extraordinarily aggressive and incorporates a long latency amount. Hence, cases are typically not detected till the disease has reached the advanced stages of cancer. As a result the prognosis for such patients is usually not favorable; the mesothelioma survival rate following diagnosis is typically simply a year or 2. That doesn’t mean, however, that there won’t be exceptions which this dour outlook won’t amendment in years to come back, particularly as additional and higher treatments are developed. Read more…

Apr
22

International Symposium On Malignant Mesothelioma 2008

Leading international consultants on the asbestos-related cancer, mesothelioma, can be a part of meso patients, caregivers, loved ones and advocates to share the most recent in treatment, analysis and clinical trials at the Mesothelioma Applied analysis Foundation’s International Symposium on Malignant Mesothelioma, 2008, Thursday, June twenty six – Saturday, June twenty eight at the Hyatt Regency on Capitol Hill, in Washington, D.C.

The Symposium, organized annually by the Meso Foundation, can highlight the most recent advances in analysis and treatment for patients and caregivers, provide psychosocial support to them still as people who have lost somebody to the disease, and supply important advocacy and volunteer opportunities for all who are intent on eradicating the vicious and terminal effects of this tragic cancer.

Day 1: Advocacy, Thursday, June twenty six could be a rallying cry to the House of Representatives to maneuver quickly on legislation banning asbestos and providing analysis funding for meso and asbestos connected diseases. This legislation should be conferenced with the companion bill within the Senate and signed into law by the President before year-end. The second advocacy objective is to request that the Senate’s Defense Appropriations Subcommittee maintain, for a second year, mesothelioma’s eligibility to compete for medical analysis funding from the Department of Defense. Read more…

Apr
22

Mesothelioma Victims Center To Assist All Victims Of Mesothelioma

Americas Watchdog has simply opened its Mesothelioma Victims Center, as the simplest way to help and defend victims of a rare type of cancer known as Mesothelioma. The service is liberated to Mesothelioma victims or their families.

Until a friend was diagnosed with Mesothelioma, Americas Watchdog had never heard of this disease or knew a lot of concerning it. Mesothelioma may be a rare and lethal type of cancer. Mesothelioma is caused by exposure to asbestos. The cluster never realized that there was no safety internet for victims, to urge facilitate from the govt.. They didn’t knowledge tough it would be to urge veterans advantages or social security advantages. Americas Watchdog additionally discovered that it’s important for victims of this lethal disease to urge correct legal illustration. they need designed the Mesothelioma Victims Center to be the national advocacy center for the victims and members of the family of Mesothelioma.Their service is free.

Their services include:

- aiding the victims acquire Social Security permanent incapacity payments
- If the victim may be a veteran and was exposed to asbestos throughout military duty, we’ll work with the victim and his/her family in getting veterans incapacity and health care advantages.
- we’ll assist the family in obtaining the most effective doable health care choices
- we’ll assist the victim in obtaining legal illustration.
- we’ll assist the victim and their family in obtaining counseling on a good type of topics that arise from this disease. A victim of Mesothelioma or their family will decision the cluster any time at 866-714-6466. Read more…

Apr
22

Human Disease Reproduced In Mouse Model For Mesothelioma

Scientists have established a mouse model for human malignant mesothelioma (MM) which will offer valuable insight into cancer development and progression along side new directions for style of therapeutic ways. The analysis, revealed by Cell Press within the March issue of Cancer Cell, could eventually result in a substantially improved outlook for patients with this devastating disease.

MM is an aggressive cancer originating from the mesothelial lining of the pleural cavity. MM is related to asbestos exposure and is characterised by an extended latency amount between exposure and disease onset. Chemotherapy will generally result in improvement of overall survival however there’s no cure for MM and patients usually succumb from the disease inside a year of diagnosis. “There is an urgent would like for experimental models of MM that may be used to not solely study the onset and progression of the disease, however additionally to function a model to pick new combination therapies and targeted agents,” says study leader, Dr. Anton Berns, from The Netherlands Cancer Institute.

In humans, MM has been related to genetic lesions that lead to the loss of Neurofibromatosis kind two (NF2) and genetic lesions affecting RB and P53 pathways. Dr. Berns’ team investigated whether or not a variety of conditional single or compound mutations within the Nf2, p53 and Rb pathways inside the mesothelial lining of the thoracic cavity would cause MM in mice.
Read more…

Apr
20

NCGR Software Enables Identification Of Mutated Genes Unique To Mesothelioma Tumors

The National Center for Genome Resources (NCGR) announced the launch of the primary web-based software system specifically designed for analysis of ultra-high throughput DNA sequencing comes. The new software system, AlpheusTM, can enable researchers to realize highly scientifically meaningful results from large DNA sequencing comes. Researchers from Brigham and Women’s Hospital (BWH) announced nowadays that that they had used AlpheusTM to get the distinctive genetic mutations of cancerous tumors in individual patients. This new approach could dramatically improve therapeutic selections for cancer patients.

BWH researchers used AlpheusTM to investigate the DNA sequences of all genes expressed in tumors from four patients with mesothelioma, an asbestos caused cancer of the lung. Approximately 266 million bases of expressed genes were sequenced per patient in collaboration with 454 Life Sciences, Inc., and analyzed with AlpheusTM software. AlpheusTM was collaboratively developed with BWH researchers to pipeline ultra-high throughput DNA sequences, enabling comparisons between patients and with reference databases to spot candidate mutations, that were validated by freelance ways. within the four mesothelioma tumors fifteen novel mutations of multiple varieties were discovered and every mesothelioma tumor had a singular mutation profile. None of the mutated genes has ever been implicated in mesothelioma. every tumor had a singular mutation profile, almost like having a singular fingerprint. The analysis results are revealed within the February twenty five, 2008 issue of the Proceedings of the National Academy of Sciences.
Read more…

Apr
20

New York Supreme Court Justice Orders Joint Trial For Two Asbestos/Mesothelioma Legal Claims

Two big apple Mesothelioma/asbestos legal claims involving asbestos exposure within the workplace, filed by Levy Philips & Konigsberg, LLP, are joined for trial based mostly upon a recent legal court call. On September twenty four, 2007, Justice Marcy S. Friedman, Supreme Court, big apple County, located in downtown big apple town, announced a ruling that joins the 2 mesothelioma cases, each being legal claims for mesothelioma/asbestos exposure within the workplace, for one trial to start on November five, 2007.

The Court’s Order joins the cases of Joel and Sharon Rosenberg v. Alpha Wire Company, et. al, Index No. 106697/06 and Joseph and Dolores Casale, Index No. 104299/06. Mr. Rosenberg resided in Jackson, New Jersey when he developed pleural mesothelioma because of workplace asbestos exposure; he died from this asbestos cancer at the age of sixty four. Mr. Casale, who resides with pleural mesothelioma at the age of sixty five, resides in Lantana, Florida. Mesothelioma attorneys from Levy Phillips & Konigsberg LLP filed these legal claims concerning asbestos/mesothelioma within the big apple town Asbestos Litigation, as every man suffered vital exposure to asbestos whereas operating in big apple town.

Mr. Rosenberg, a life-long electrician with the International Brotherhood of Electrical employees (“IBEW”), Local 3, started within the trade whereas still an adolescent in 1960. Mr. Rosenberg’s workplace asbestos exposure occurred whereas operating within the electrician trade in work sites in big apple. Read more…

Apr
20

New Clinical Trial To Test Effectiveness Of Vorinostat (Zolinza) On Malignant Pleural Mesothelioma

A part III clinical trial is underway, in Maryland, at the National Institutes of Health Clinical Center, to work out how effective vorinostat is at treating patients with pleural malignant mesothelioma . analysis is underway specifically concerning Vorinostat, conjointly called suberoylanilide hydroxamic acid, is marketed beneath the name Zolinza. This mesothelioma clinical trial can attempt to ascertain the amount of toxicity furthermore as any aspect effects that are occasioned in patients who are prescribed Vorinostat (Zolinza) and to match these results against those of patients who are administered a placebo.

The title for this ongoing project is “A part III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy ” Raffit Hassan, MD, is that the protocol chair for this study. The expected enrollment for the mesothelioma clinical trial study is 660 mesothelioma patients.

All patients during this malignant mesothelioma analysis study should have a histologically or cytologically confirmed diagnosis of pleural mesothelioma, which can be of the epithelial, sarcomatoid or mixed sub-type. All patients should even have previously skillful one or two commonplace systemic mesothelioma treatments that included pemetrexed disodium and either cisplatin or carboplatin. Researches on behalf of the mesothelioma clinical trial hope for a few positive results and low aspect effects within the trial study of Vorinostat. Read more…

Apr
16

UK Government Takes Action On Mesothelioma

People with a chest cancer associated with exposure to asbestos can receive a lift, as a brand new framework for improving their care is launched by Health Minister Rosie Winterton.

Marking Action Mesothelioma Day, Rosie Winterton can announce the publication of the National Mesothelioma Framework at an incident at Gateshead Millennium Bridge.

The new framework provides recommendation to the NHS on the way to organise services for mesothelioma patients so as to enhance quality of care, building on the structures already in place for lung cancer patients. it’s hoped that the NHS can adopt the recommendations started out within the Framework to make sure higher take care of mesothelioma patients and their families.

Health Minister Rosie Winterton said:

“Mesothelioma will be a difficult condition for the NHS to diagnose and manage, particularly because the range of cases varies round the country so, in some areas, it’s a rare condition.

“It is vital that we tend to work to enhance quality of care to a uniformly high level across the country. With a possible peak of cases but 10 years away, we’ve a window of chance currently to make sure that the NHS has done all it will to supply a top quality service for all mesothelioma patients.

“I am so more than happy to be launching the National Mesothelioma Framework nowadays.”

Dame Helena Shovelton, Chief government of the British Lung Foundation said:

“We welcome this initiative by the Department of Health to enhance services for folks with the asbestos-caused cancer mesothelioma. The Action Mesothelioma Charter necessitate the disease to be created a national priority. This initiative can facilitate to make sure that individuals with this cruel disease currently have a much better likelihood of receiving the simplest treatment and care.”

Chris Knighton of the Mick Knighton Mesothelioma analysis Fund said:

“Action Mesothelioma Day offers a far required chance to push a bigger awareness into the risks of asbestos – past, gift and future. the united kingdom faces a virulent disease of mesothelioma, nonetheless awareness of the hazard of asbestos remains dangerously low.

“Mesothelioma could be a cruel disease with, as yet, no cure and it’s important that individuals perceive that they still have to be compelled to be vigilant regarding asbestos. Anyone who comes into contact with it might be in danger.”

The Framework is predicated on recommendation from the National Lung Cancer and Mesothelioma Advisory cluster and takes on board comments from a public consultation.

Notes:

The Framework is out there on the Department of Health web site at http://www.dh.gov.uk

What is mesothelioma?

Mesothelioma could be a cancer that principally affects the liner of the lungs (pleura). but it also can have an effect on the peritoneum (a skinny lining within the abdomen). Over ninetieth per cent of mesothelioma affects the liner of the lungs.

What causes mesothelioma?

Mesothelioma includes a terribly robust association with exposure to asbestos. When asbestos fibres are inhaled, malignant modification happens during a proportion of people and willcer of the liner of the lungs can follow. it’s believed that just about all deaths caused by mesothelioma are linked to asbestos exposure.

How many mesothelioma cases are there?

There are around 1800 new cases of mesothelioma a year in England and therefore the disease is nearly forever fatal. Mesothelioma is predicted to become a lot of common over consequent 5 to 10 years because the effects of this exposure become apparent.

Where do cases of mesothelioma typically occur?

There are pockets of mesothelioma round the country typically linked to areas that had ship building, significant engineering (which used important amounts of asbestos) and asbestos product producing industries.

However, there additionally|also are|are} incidences in alternative areas as folks move far from industrial areas and also as a result of mesothelioma will occur in people who return into contact with asbestos within the building trade or through operating in buildings where asbestos construction materials are used and become disturbed in how.

Men are much more probably to develop mesothelioma than ladies, mainly as a result of they were a lot of probably to possess been exposed to asbestos within the course of their work. However, there also can be cases of relatives exposed to asbestos fibres on work garments.

More info on Action Mesothelioma Day is out there on the British Lung Foundation web site at http://www.lunguk.org

Apr
16

Alfacell Corporation Granted U.S. Orphan Drug Designation For ONCONASE(R) For Treatment Of Malignant Mesothelioma

Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company targeted on the invention, development and commercialization of novel ribonuclease therapeutics for cancer, these days announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation within the u.  s. for the company’s lead drug candidate, ONCONASE(R) (ranpirnase), for treatment of malignant mesothelioma. Alfacell is evaluating ONCONASE during a confirmatory part IIIb clinical trial in unresectable malignant mesothelioma (UMM).

Orphan drug designation permits Alfacell to be awarded seven years of selling exclusivity for ONCONASE for the malignant mesothelioma indication upon FDA approval for this indication. different edges that Alfacell is eligible with the orphan drug designation embody protocol help by the FDA within the preparation of a dossier that may meet regulatory necessities, tax credits, analysis and development grant funding, and reduced filing fees for the selling application.

“Orphan-drug designation within the u.  s. is a vital milestone for everybody related to Alfacell, as well as malignant mesothelioma patients, investors and staff,” said Kuslima Shogen, the company’s chairman and chief govt officer. “This designation represents recognition of the potential of our lead drug candidate by the FDA, additionally to the previously granted fast-track development standing within the u.  s., in addition because the orphan-drug designations received in Europe and Australia for malignant mesothelioma. Moreover, it is a important event for us in what’s a transformational year for our company.”

The FDA orphan drug designation provides incentives to pharmaceutical and biotechnology corporations to develop medication for the treatment of diseases affecting fewer than two hundred,000 individuals within the u.  s.. Malignant mesothelioma qualifies below this demand as a result of approximately four,000 to 5,000 new cases are reported within the u.  s. every year.

About ONCONASE(R)

ONCONASE may be a first-in-class therapeutic from Alfacell’s proprietary ribonuclease (RNase) technology platform. ONCONASE has been shown in vitro and in vivo to focus on tumor cells whereas sparing traditional cells. ONCONASE is internalized by endocytosis and released into the cytosol of the cancerous cell, where it selectively degrades tRNA beyond repair. In doing thus, ONCONASE inhibits protein synthesis, stops cell cycle proliferation, and induces apoptosis (programmed cell death).

In addition to the continuing confirmatory part IIIb registration study in malignant mesothelioma, the corporate is conducting an ONCONASE part I/II trial in Non-Small Cell Lung Cancer (NSCLC) and different solid tumors.

About Alfacell Corporation

Alfacell Corporation may be a biopharmaceutical company using proprietary ribonuclease (RNase) technology within the discovery, development and commercialization of novel therapeutics for cancer and different life-threatening diseases. For additional info, please visit http://www.alfacell.com.

Safe Harbor

This press unleash includes statements that will represent “forward- looking” statements, sometimes containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that would cause actual results to differ materially from the forward-looking statements. Factors that may cause or contribute to such variations embody, however aren’t restricted to, uncertainties concerned in transitioning from concept to product, uncertainties involving the flexibility of the corporate to finance analysis and development activities, potential challenges to or violations of patents, uncertainties concerning the result of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and different risks mentioned within the Company’s periodic filings with the Securities and Exchange Commission. By creating these forward-looking statements, the corporate undertakes no obligation to update these statements for revisions or changes once the date of this unleash.

Apr
16

Alfacell Updates Progress On Clinical Development Program For ONCONASE(R) In Malignant Mesothelioma

Alfacell Corporation (Nasdaq: ACEL) announced these days an update relating to the continuing randomized, multi-center, multi-national, confirmatory part IIIb registration study for its lead anti-cancer drug, ONCONASE(R) (ranpirnase). This pivotal trial is evaluating the effectiveness of ONCONASE and doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone.

The Company’s Chief govt Officer and Chairman of the Board of administrators, Kuslima Shogen, commented, “As a results of our recently completed financing we tend to are during a sturdy position to more accelerate our clinical and regulatory strategy for ONCONASE. To date, we’ve accrued over 360 patients, and are awaiting the 316 events needed to trigger the ultimate analysis. we glance forward to finishing the study and to adhering closely to our desired essential path, that centers on positive results from the ultimate analysis resulting in the filing of an NDA.”

Shogen stated, “ONCONASE has previously been granted quick Track standing by the FDA for UMM, that permits us the chance to submit sections of an NDA as they’re ready. As such, we tend to are continuing to finalize elements of the Chemistry producing and Controls (CMC) section, that we tend to conceive to submit by finish of third quarter 2006.”

Shogen concluded, “Overall, we tend to are happy with the consistent progress the corporate has created within the ONCONASE UMM clinical program, which we tend to stay not off course with our previously stated timelines. we glance forward to providing future updates on our progress toward selling approval, also as ongoing and new ONCONASE trials in major cancers.”

About ONCONASE(R)

ONCONASE may be a first-in-class therapeutic from Alfacell’s proprietary ribonuclease (RNase) technology platform. ONCONASE has been shown to focus on tumor cells whereas sparing traditional cells. ONCONASE is internalized by endocytosis and released into the cytosol of the cancerous cell, where it selectively degrades tRNA beyond repair. In doing therefore, ONCONASE inhibits protein synthesis, stops cell cycle proliferation, and induces apoptosis (programmed cell death).

ONCONASE has previously been granted Orphan Drug designation from EMEA and TGA (Australia), also as quick Track standing by the FDA. the corporate is additionally conducting an ONCONASE part I / II trial in Non-Small Cell Lung Cancer (NSCLC).

About Alfacell Corporation

Alfacell Corporation may be a biopharmaceutical company targeted on the invention, development and commercialization of novel therapeutics for cancer and different life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. For a lot of info, please visit http://www.Alfacell.com.

This press unharness includes statements which will represent “forward- looking” statements, typically containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that might cause actual results to differ materially from the forward-looking statements. Factors that might cause or contribute to such variations embrace, however don’t seem to be restricted to, uncertainties concerned in transitioning from concept to product, uncertainties involving the power of the corporate to finance analysis and development activities, potential challenges to or violations of patents, uncertainties relating to the result of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and different risks mentioned within the Company’s periodic filings with the Securities and Exchange Commission. By creating these forward-looking statements, the corporate undertakes no obligation to update these statements for revisions or changes once the date of this unharness.

Apr
14

CuraGen And TopoTarget Announce Initiation Of NCI-sponsored Phase II Clinical Trial With PXD101 For Mesothelioma

CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced nowadays the initiation of patient dosing during a part II clinical trial evaluating the activity of PXD101, alittle molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National Cancer Institute (NCI) underneath a Clinical Trials Agreement with CuraGen for the clinical development of PXD101.

The part II clinical trial is an open-label study being led by Suresh Ramalingam, M.D., Assistant Professor of medication at the University of Pittsburgh college of medication in Pittsburgh, PA. Patients with unresectable malignant pleural mesothelioma, who have failed one previous line of chemotherapy, are enrolled and receive PXD101 by intravenous infusion each 3 weeks. the first endpoint for the study is response rate, with secondary endpoints evaluating safety and measuring each the time to treatment failure and survival. a complete of roughly thirty seven patients are expected to be enrolled into this study at multiple sites across the u.  s..

“A important quantity of preclinical analysis suggests that HDAC inhibitors, together with PXD101, alter the regulation of the many genes, leading to growth inhibition of human mesothelioma cells. Given the flexibility of HDAC inhibitors to down-regulate genes like BCL-XL and VEGF and up-regulate cell-cycle regulating genes, together with p21, we have a tendency to are excited to start evaluating PXD101 as a possible treatment for this sort of cancer,” stated Dr. Ramalingam. “There are not any proven treatment choices beyond the first-line chemotherapy regimen for mesothelioma, highlighting the importance of evaluating promising therapeutics like PXD101 for this patient population.”

Correlative pharmacodynamic studies will be conducted to judge the potential inhibition of HDACs in mesothelioma tumor cells from patients enrolled during this trial. analysis of the genes regulating proliferation and apoptosis (programmed cell death), similarly as acetylation of histone and non-histone proteins, are performed.

About Mesothelioma

As several as three,000 new cases of malignant mesothelioma are expected to be diagnosed within the u.  s. in 2006. Mesothelioma may be a form of cancer arising from the cells, referred to as mesothelium, with the bulk of cancers starting within the chest cavity. The incidence of mesothelioma will increase with age and is never diagnosed in patients underneath fifty five years recent. though environmental exposure to bound chemicals and radiation are believed to play a job within the development of mesothelioma, exposure to asbestos is believed to be the most reason behind mesothelioma. The five-year survival rate for mesothelioma is approximately 100 percent, with a median survival of 1 to 2 years following diagnosis.

PXD101 may be a promising little molecule HDAC inhibitor being investigated for its role within the treatment of a large vary of solid and hematologic malignancies either as a single-agent, or together with alternative active anti-cancer agents, together with 5-fluorouracil (5-FU), carboplatin, paclitaxel and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a brand new mechanistic category of anti-cancer therapeutics that concentrate on HDAC enzymes and are shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to beat drug resistance when employed in combination with alternative anti-cancer agents.

PXD101 is currently being evaluated in multiple clinical trials as a possible treatment for multiple myeloma, T-cell lymphoma, and colorectal and ovarian cancers, either alone or together with anti-cancer therapies. In August 2004, CuraGen signed a Clinical Trials Agreement with the NCI underneath that the NCI can sponsor many clinical trials to research PXD101 for the treatment of varied cancers, each as a single-agent and together chemotherapy regimens. In might 2005, TopoTarget announced the signing of a Cooperative analysis and Development Agreement (CRADA) with the NCI to conduct pre-clinical and non-clinical studies on PXD101 so as to higher perceive its anti-tumor activity and to produce supporting data for clinical trials.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) may be a biopharmaceutical company developing numerous approaches, together with novel protein, antibody, and little molecule therapeutics, that aim to supply hope for patients with cancer, inflammatory diseases, and diabetes. CuraGen’s strategic alliances have resulted during a deep pipeline of potential therapeutics that’s being developed by the Company’s experienced analysis and development groups. By leveraging the drug development strengths cultivated over the years, CuraGen expects to create a distinction within the lives of patients by bringing forward promising therapeutics that address unmet medical wants. To any exploit CuraGen’s intensive analysis and development experience, CuraGen founded a majority-owned subsidiary, 454 Life Sciences, that has developed and is commercializing advanced technologies for the sequencing of DNA. CuraGen and 454 Life Sciences are headquartered in Branford, Connecticut. for added data on the businesses please visit http://www.curagen.com and http://www.454lifesciences.com.

About TopoTarget

TopoTarget (CSE: TOPO) may be a totally integrated biopharmaceutical company, headquartered in Denmark and with subsidiaries within the UK and Germany, and dedicated to finding “Answers for Cancer” and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical expertise with in-depth understanding of the molecular mechanisms of cancer. Focus lies on key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a powerful development foundation of proprietary, highly predictive cancer models has been designed. TopoTarget encompasses a broad portfolio of little molecule preclinical drug candidates and eight medication are in clinical development, consisting of each novel anti-cancer therapeutics and new cancer indications for existing medication. the foremost advanced drug candidate, Savene(tm) for extravasations is anticipated on the market finish 2006. additionally to organic growth, TopoTarget consistently appearance for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For a lot of data, please consult with http://www.topotarget.com.

Safe Harbor

This press unharness contains forward-looking statements together with statements concerning the expected effects and edges of PXD101. we have a tendency to caution investors that there is no assurance that actual results or business conditions won’t differ materially from those projected or prompt in such forward-looking statements as a results of numerous factors, including, however not restricted to, the following: the danger that anyone or a lot of of the PXD101 or the other CuraGen drug development program won’t proceed as planned for technical, scientific or industrial reasons or thanks to patient enrollment problems or primarily based on new data from nonclinical or clinical studies or from alternative sources; the success of competing product and technologies; technological uncertainty {and product|and merchandise|and product} development risks; uncertainty of further funding; CuraGen’s history of incurring losses and also the uncertainty of achieving profitability; CuraGen’s stage of development as a biopharmaceutical company; government regulation; patent infringement claims against CuraGen’s products, processes and technologies; the flexibility to shield CuraGen’s patents and proprietary rights; uncertainties regarding commercialization rights; and products liability exposure. Please consult with CuraGen’s Annual and Quarterly Reports on Forms 10-K and 10-Q for a whole description of those risks. CuraGen disclaims any intention or obligation to update or revise any forward-looking statements, whether or not as a results of new data, future events, or otherwise, unless needed by law.

Popular Search Terms

topotarget event -senyheder, warnings on pleural effusion, PROGNOSIS WITH ALIMTA FOR MESOTHELIOMA, levy phillips, a personal is
Go back to top